Shilpa Medicare Limited
Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics.
What Shilpa files
- Important41
- Updates40
- Others36
- Investor Meet26
- Board Meeting14
- PPTs8
Shilpa Medicare's board has approved the financial results for the quarter and half-year ended September 30, 2025. Both standalone and consolidated results have been given the go-ahead. **Investor Alert:** The provided document confirms the approval of these results but does not contain the actual financial figures for total revenue, net...
Shilpa Medicare Limited has announced a board meeting to discuss the integrated financial results for the quarter and nine months ended December 31, 2024. The standalone revenue from operations decreased to ₹12,538.66 crore, while total income was ₹14,221.24 crore. The company reported a net profit of ₹2,533.07 crore for the...